Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms

被引:0
|
作者
Deng Bo [1 ]
Jia Liqun [1 ]
Tan Huangying [1 ]
Lou Yanni [1 ]
Li Xue [1 ]
Li Yuan [1 ]
Yu Lili [1 ]
机构
[1] China Japan Friendship Hosp, Integrat Oncol Dept, Beijing 100029, Peoples R China
关键词
UGT1A1; enzyme; Diarrhea; Irinotecan; Shengjiangxiexin decoction; COLORECTAL-CANCER PATIENTS; INDUCED DIARRHEA; OXALIPLATIN; UGT1A;
D O I
暂无
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
OBJECTIVE: To evaluate the efficacy of Shengjiangxiexin decoction (SXD), prepared with a formula from Traditional Chinese Medicine (TCM), in reducing irinotecan-induced hematological and gastrointestinal toxicities in patients with UDP-glucuronosyltransferase (UGT)1A1*28 and UGT1A1*6 polymorphisms. METHODS: This clinical trial included 115 patients receiving irinotecan combined with 5-fluorouracil plus 1-leucovorin (FOLFIRI) treatment. All patients consented to UGT1A1*28 and *6 gene polymorphism detection prior to chemotherapy. SXD were administered from 1 day prior to chemotherapy to 6 day post chemotherapy. Chemotherapy induced adverse reactions (neutropenia, diarrhea, nausea, vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly." RESULTS: A total of 50 patients had *1/*1 wild genotype, 58 patients had single allele variants with genotype *1/*6 or *1/*28, and 7 patients had two alleles variants with genotype *6/*6, *28/*28 or *61* 28. In *1/*6 or *1/*28 patients (high risk group),.9 patients (15.5%) developed I II grade diarrhea and no patient developed severe diarrhea; neutropenia occurred in 19 patients (32.8%) and only 3 patients (8.6%) developed sever neutropenia. There were no significant differences in any toxic effects (neutropenia, diarrhea, nausea, vomiting, anorexia or infection) between *6 or *28 variant patients (high risk group) and wild type patients. No sever toxicity was found in high risk two alleles variants patients (*6/*6, *6/*28 or *28/*28). No significant differences were observed between UGT1A1*6/*28 polymorphisms and clinical response of chemotherapy. CONCLUSION: SXD could significantly reduce irinotecan-induced hematological and gastrointestinal toxicities in UGT1A1*28 or *6 variant patients (high risk group), while this treatment didn't affect clinical response of chemotherapy. (C) 2017 JTCM. All rights reserved.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 50 条
  • [21] Irinotecan-induced neutropenia and UGT1A1*28: Does dose matter?
    Hoskins, J. M.
    Goldberg, R. M.
    McLeod, H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients
    Jing Gao
    Jun Zhou
    Yanyan Li
    Zhi Peng
    Yilin Li
    Xicheng Wang
    Lin Shen
    Medical Oncology, 2013, 30
  • [23] Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients
    Gao, Jing
    Zhou, Jun
    Li, Yanyan
    Peng, Zhi
    Li, Yilin
    Wang, Xicheng
    Shen, Lin
    MEDICAL ONCOLOGY, 2013, 30 (03)
  • [24] Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia
    Teh, L. K.
    Hashim, H.
    Zakaria, Z. A.
    Salleh, M. Z.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2012, 136 (02) : 249 - 259
  • [25] Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients
    Jada, Srinivasa Rao
    Lim, Robert
    Wong, Chiung Ing
    Shu, Xiaochen
    Lee, Soo Chin
    Zhou, Qingyu
    Goh, Boon Cher
    Chowbay, Balram
    CANCER SCIENCE, 2007, 98 (09): : 1461 - 1467
  • [26] Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1☆28 and/or UGT1A1☆6 polymorphisms
    Satoh, Taroh
    Ura, Takashi
    Yamada, Yasuhide
    Yamazaki, Kentaro
    Tsujinaka, Toshimasa
    Munakata, Masaki
    Nishina, Tomohiro
    Okamura, Shu
    Esaki, Taito
    Sasaki, Yasutsuna
    Koizumi, Wasaburo
    Kakeji, Yoshihiro
    Ishizuka, Naoki
    Hyodo, Ichinosuke
    Sakata, Yuh
    CANCER SCIENCE, 2011, 102 (10) : 1868 - 1873
  • [27] Linkage disequilibrium of UGT1A1*6 and UGT1A1*28 in relation to UGT1A6 and UGT1A7 polymorphisms
    Urawa, Naohito
    Kobayashi, Yoshinao
    Araki, Jun
    Sugimoto, Ryosuke
    Iwasa, Motoh
    Kaito, Masahiko
    Adachi, Yukihko
    ONCOLOGY REPORTS, 2006, 16 (04) : 801 - 806
  • [28] Profiling of UGT1A1*6, UGT1A1*60, UGT1A1*93, and UGT1A1*28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
    Amandito, Radhian
    Rohsiswatmo, Rinawati
    Carolina, Erica
    Maulida, Rizka
    Kresnawati, Windhi
    Malik, Amarila
    FRONTIERS IN PEDIATRICS, 2019, 7
  • [29] UGT1A1*20 and other UGT1A polymorphisms as determinants of irinotecan toxicity
    Biason, P.
    Masier, S.
    Toffoli, G.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (02) : 158 - 165
  • [30] Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
    Rouits, E
    Boisdron-Celle, M
    Dumont, A
    Guérin, O
    Morel, A
    Gamelin, E
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 5151 - 5159